BridgeBio Pharma, Inc. Payments To Acquire Equity Securities Fv Ni
BridgeBio Pharma, Inc. (BBIO) reported Payments To Acquire Equity Securities Fv Ni of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquitySecuritiesFvNi · last filed 2026-02-24
- BridgeBio Pharma, Inc. payments to acquire equity securities fv ni for the quarter ending 2025-12-31 was $0.00.
- BridgeBio Pharma, Inc. payments to acquire equity securities fv ni for the quarter ending 2025-09-30 was $0.00.
- BridgeBio Pharma, Inc. payments to acquire equity securities fv ni for the quarter ending 2025-06-30 was $0.00.
- BridgeBio Pharma, Inc. payments to acquire equity securities fv ni for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BridgeBio Pharma, Inc. payments to acquire equity securities fv ni for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- BridgeBio Pharma, Inc. payments to acquire equity securities fv ni for fiscal 2024 was $20.27M, a 81.15% decline from fiscal 2023.
- BridgeBio Pharma, Inc. payments to acquire equity securities fv ni for fiscal 2023 was $107.54M, a 93.55% increase from fiscal 2022.
- BridgeBio Pharma, Inc. payments to acquire equity securities fv ni for fiscal 2022 was $55.56M, a 4.08% increase from fiscal 2021.
| Period end | Payments To Acquire Equity Securities Fv Ni 3 month | Payments To Acquire Equity Securities Fv Ni 6 month | Payments To Acquire Equity Securities Fv Ni 9 month | Payments To Acquire Equity Securities Fv Ni 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 10-K · filed 2026-02-24 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $0.00 10-Q · filed 2025-10-29 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2025-03-31 | $0.00 10-Q · filed 2025-04-29 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $0.00 derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | $20.27M 10-K · filed 2026-02-24 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $20.27M 10-Q · filed 2025-10-29 | $49.49M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $20.27M 10-Q · filed 2025-08-05 | $49.49M derived: sum of 3 quarters · filed 2026-02-24 | $56.30M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $20.27M 10-Q · filed 2025-04-29 | $49.49M derived: sum of 2 quarters · filed 2026-02-24 | $56.30M derived: sum of 3 quarters · filed 2026-02-24 | $80.33M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $29.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $36.03M derived: sum of 2 quarters · filed 2026-02-24 | $60.06M derived: sum of 3 quarters · filed 2026-02-24 | $107.54M 10-K · filed 2026-02-24 |
| 2023-09-30 | $6.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $30.84M derived: sum of 2 quarters · filed 2024-11-12 | $78.31M 10-Q · filed 2024-11-12 | $107.56M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $24.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $71.50M 10-Q · filed 2024-08-01 | $100.75M derived: sum of 3 quarters · filed 2025-02-20 | $116.14M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $47.47M 10-Q · filed 2024-05-02 | $76.72M derived: sum of 2 quarters · filed 2025-02-20 | $92.11M derived: sum of 3 quarters · filed 2025-02-20 | $94.87M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $29.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $44.63M derived: sum of 2 quarters · filed 2025-02-20 | $47.40M derived: sum of 3 quarters · filed 2025-02-20 | $55.56M 10-K · filed 2025-02-20 |
| 2022-09-30 | $15.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $18.15M derived: sum of 2 quarters · filed 2023-11-02 | $26.31M 10-Q · filed 2023-11-02 | $55.73M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $10.93M 10-Q · filed 2023-08-03 | $40.35M derived: sum of 3 quarters · filed 2024-02-22 | $44.31M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $8.16M 10-Q · filed 2023-05-04 | $37.59M derived: sum of 2 quarters · filed 2024-02-22 | $41.55M derived: sum of 3 quarters · filed 2024-02-22 | |
| 2021-12-31 | $29.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $33.38M derived: sum of 2 quarters · filed 2024-02-22 | $53.38M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $3.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $23.96M 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $20.00M 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |